J. Goldman

Hematology · New England Journal of Medicine · 1986–2013

A researcher in the Science corpus: 17 papers; trusts 1 researcher and is trusted by 6 researchers here, as inferred from the citation graph.

Subfields

• Hematology — 92 citations into it; #25 of 225 by trust here, #7 by citations

Whom J. Goldman trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. Brian J. Druker

Who trusts J. Goldman overall

1. H. Zahreddine
2. Brian J. Druker
3. K. Borden
4. B. Huntly

Papers from J. Goldman's perspective

Ordered by how strongly the researchers J. Goldman trusts endorse each paper. Same corpus, a different order for every researcher.

1. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. (Journal of Clinical Oncology)
2. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. (Cancer Cell)
3. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. (The Lancet Oncology)
4. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. (Blood)
5. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. (Blood)
6. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. (Journal of Clinical Oncology)
7. The molecular biology of chronic myeloid leukemia. (Blood)
8. Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
9. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. (Blood)
10. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. (Blood)

Their papers

• A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias (2013) — 1,031 citations
• European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. (2013) — 1,917 citations
• Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. (2010) — 918 citations
• International randomized study of interferon Vs STI571 (IRIS) 8-year follow up: Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (2009) — 672 citations
• Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. (2009) — 1,280 citations
• Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. (2006) — 1,349 citations
• Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. (2006) — 3,470 citations
• Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. (2003) — 3,629 citations
• Chronic myeloid leukemia--advances in biology and new approaches to treatment. (2003) — 982 citations
• Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. (2003) — 1,294 citations
• Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. (2002) — 1,213 citations
• Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. (2002) — 609 citations
• Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. (2002) — 1,073 citations
• Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. (2002) — 2,100 citations
• The molecular biology of chronic myeloid leukemia. (2000) — 1,713 citations
• Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. (2000) — 839 citations
• Graft rejection following HLA matched T‐lymphocyte depleted bone marrow transplantation (1986)